治疗抵抗性抑郁症的个体和社会负担：概述。
The Individual and Societal Burden of Treatment-Resistant Depression: An Overview.
机构信息
Department of Psychiatry, Center for Depression Research and Clinical Care, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75235, USA.
Department of Psychiatry, Center for Depression Research and Clinical Care, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75235, USA; O'Donnell Brain Institute, UT Southwestern Medical Center, 6363 Forest Park Road, Dallas, TX 75235, USA.
出版信息
Psychiatr Clin North Am. 2023 Jun;46(2):211-226. doi: 10.1016/j.psc.2023.02.001.
Abstract
Major depressive disorder is characterized by depressed mood and/or anhedonia with neurovegetative symptoms and neurocognitive changes affecting an individual's functioning in multiple aspects of life. Treatment outcomes with commonly used antidepressants remain suboptimal. Treatment-resistant depression (TRD) should be considered after inadequate improvement with two or more antidepressant treatments of adequate dose and duration. TRD has been associated with increased disease burden including higher associated costs (both socially and financially) affecting both the individual and society. Additional research is needed to better understand the long-term burden of TRD to both the individual and society.
摘要
重性抑郁障碍的特征为情绪低落和/或快感缺失，伴有神经植物性症状和神经认知改变，影响个体生活的多个方面的功能。常用抗抑郁药的治疗效果仍不理想。在充分剂量和足够疗程的两种或两种以上抗抑郁药物治疗后未见充分改善，应考虑治疗抵抗性抑郁症（TRD）。TRD 与疾病负担增加相关，包括更高的相关成本（社会和经济两方面），影响个体和社会。需要进一步研究以更好地了解 TRD 对个体和社会的长期负担。
相似文献
1
The Individual and Societal Burden of Treatment-Resistant Depression: An Overview.治疗抵抗性抑郁症的个体和社会负担：概述。
Psychiatr Clin North Am. 2023 Jun;46(2):211-226. doi: 10.1016/j.psc.2023.02.001.
2
A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough?针对抑郁患者治疗抵抗的临床方法：当常规治疗效果不够好时该怎么办？
World J Biol Psychiatry. 2021 Sep;22(7):483-494. doi: 10.1080/15622975.2020.1851052. Epub 2020 Dec 8.
3
Overview of treatment-resistant depression.治疗抵抗性抑郁症概述。
Prog Brain Res. 2023;278:1-23. doi: 10.1016/bs.pbr.2023.03.007. Epub 2023 May 15.
4
Association of Treatment-Resistant Depression With Patient Outcomes and Health Care Resource Utilization in a Population-Wide Study.在一项基于人群的研究中，治疗抵抗性抑郁症与患者结局和医疗资源利用的关系。
JAMA Psychiatry. 2023 Feb 1;80(2):167-175. doi: 10.1001/jamapsychiatry.2022.3860.
5
The burden and the challenge of treatment-resistant depression.治疗抵抗性抑郁症的负担和挑战。
Psychiatriki. 2021 Dec;32(Supplement I):11-14. doi: 10.22365/jpsych.2021.046.
6
Early improvement and response to antidepressant medications in adults with major depressive disorder. Meta-analysis and study of a sample with treatment-resistant depression.成人重性抑郁障碍患者使用抗抑郁药物的早期改善和反应。伴有治疗抵抗性抑郁的样本的荟萃分析和研究。
J Affect Disord. 2018 Feb;227:777-786. doi: 10.1016/j.jad.2017.11.004. Epub 2017 Nov 10.
7
The Prevalence and National Burden of Treatment-Resistant Depression and Major Depressive Disorder in the United States.美国治疗抵抗性抑郁症和重度抑郁症的患病率和国家负担。
J Clin Psychiatry. 2021 Mar 16;82(2):20m13699. doi: 10.4088/JCP.20m13699.
8
Real-world data analysis of the clinical and economic burden and risk factors in patients with major depressive disorder with an inadequate response to initial antidepressants.抗抑郁药初始治疗应答不足的重度抑郁症患者的临床和经济负担及相关风险因素的真实世界数据分析。
J Med Econ. 2021 Jan-Dec;24(1):589-597. doi: 10.1080/13696998.2021.1918922.
9
Treatment-Resistant Depression: Approaches to Treatment.治疗抵抗性抑郁症：治疗方法。
J Psychosoc Nurs Ment Health Serv. 2021 Sep;59(9):7-11. doi: 10.3928/02793695-20210816-01. Epub 2021 Sep 1.
10
Prospective study of antidepressant treatment of psychiatric patients with depressive disorders: treatment adequacy and outcomes.前瞻性研究抗抑郁药物治疗伴有抑郁障碍的精神科患者：治疗充分性和结果。
BMC Psychiatry. 2023 Nov 28;23(1):888. doi: 10.1186/s12888-023-05390-8.
引用本文的文献
1
Mechanisms Underlying Treatment-Resistant Depression: Exploring Sex-Based Biological Differences.难治性抑郁症的潜在机制：探索基于性别的生物学差异。
J Neurochem. 2025 Sep;169(9):e70215. doi: 10.1111/jnc.70215.
2
Intranasal esketamine significantly alleviates depression severity and suicidal ideations in electroconvulsive therapy (ECT) non-responders.鼻内给予艾司氯胺酮可显著减轻电休克治疗（ECT）无反应者的抑郁严重程度和自杀观念。
Eur Arch Psychiatry Clin Neurosci. 2025 Jul 1. doi: 10.1007/s00406-025-02041-9.
3
Advancing Depression Management Through Biomarker Discovery with a Focus on Genetic and Epigenetic Aspects: A Comprehensive Study on Neurobiological, Neuroendocrine, Metabolic, and Inflammatory Pathways.通过生物标志物发现推进抑郁症管理，重点关注遗传和表观遗传方面：关于神经生物学、神经内分泌、代谢和炎症途径的综合研究
Genes (Basel). 2025 Apr 25;16(5):487. doi: 10.3390/genes16050487.
4
Esketamine Combined With SSRI or SNRI for Treatment-Resistant Depression.艾氯胺酮联合选择性5-羟色胺再摄取抑制剂（SSRI）或5-羟色胺及去甲肾上腺素再摄取抑制剂（SNRI）治疗难治性抑郁症
JAMA Psychiatry. 2025 Apr 2. doi: 10.1001/jamapsychiatry.2025.0200.
5
Classic Psychedelics for the Treatment of Depression: Potential Benefits and Challenges.用于治疗抑郁症的经典致幻剂：潜在益处与挑战
Drugs. 2025 May;85(5):609-626. doi: 10.1007/s40265-025-02172-2. Epub 2025 Mar 24.
6
A New Trick of Old Dogs: Can Kappa Opioid Receptor Antagonist Properties of Antidepressants Assist in Treating Treatment-Resistant Depression (TRD)?老药新用：抗抑郁药的κ阿片受体拮抗剂特性能否助力治疗难治性抑郁症（TRD）？
Pharmaceuticals (Basel). 2025 Feb 3;18(2):208. doi: 10.3390/ph18020208.
7
Exploring cariprazine as a treatment option for varied depression symptom clusters.探索卡立普嗪作为治疗多种抑郁症状群的一种选择。
Front Psychiatry. 2024 Sep 25;15:1442699. doi: 10.3389/fpsyt.2024.1442699. eCollection 2024.
8
Treatment-Resistant Depression (TRD): Is the Opioid System Involved?治疗抵抗性抑郁症（TRD）：阿片系统是否参与其中？
Int J Mol Sci. 2023 Jul 6;24(13):11142. doi: 10.3390/ijms241311142.
本文引用的文献
1
Courses of treatment and risk factors for treatment-resistant depression in Finnish primary and special healthcare: A nationwide cohort study.芬兰初级和专科保健中的治疗过程和治疗抵抗性抑郁症的风险因素：一项全国性队列研究。
J Affect Disord. 2022 Jul 1;308:236-242. doi: 10.1016/j.jad.2022.04.010. Epub 2022 Apr 6.
2
Evolution and Emerging Trends in Depression Research From 2004 to 2019: A Literature Visualization Analysis.2004年至2019年抑郁症研究的进展与新趋势：文献可视化分析
Front Psychiatry. 2021 Oct 29;12:705749. doi: 10.3389/fpsyt.2021.705749. eCollection 2021.
3
Persistent depressive symptoms during COVID-19: a national, population-representative, longitudinal study of U.S. adults.新冠疫情期间的持续性抑郁症状：一项针对美国成年人的全国性、具有人口代表性的纵向研究。
Lancet Reg Health Am. 2022 Jan;5:100091. doi: 10.1016/j.lana.2021.100091. Epub 2021 Oct 4.
4
The Growing Burden of Major Depressive Disorders (MDD): Implications for Researchers and Policy Makers.重度抑郁症（MDD）日益加重的负担：对研究人员和政策制定者的启示。
Pharmacoeconomics. 2021 Jun;39(6):619-625. doi: 10.1007/s40273-021-01040-7. Epub 2021 May 20.
5
The Prevalence and National Burden of Treatment-Resistant Depression and Major Depressive Disorder in the United States.美国治疗抵抗性抑郁症和重度抑郁症的患病率和国家负担。
J Clin Psychiatry. 2021 Mar 16;82(2):20m13699. doi: 10.4088/JCP.20m13699.
6
Depression screening and treatment among uninsured populations in Primary Care.基层医疗中未参保人群的抑郁症筛查与治疗。
Int J Clin Health Psychol. 2021 Sep-Dec;21(3):100241. doi: 10.1016/j.ijchp.2021.100241. Epub 2021 Apr 10.
7
The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018).美国患有重度抑郁症的成年人的经济负担（2010 年和 2018 年）。
Pharmacoeconomics. 2021 Jun;39(6):653-665. doi: 10.1007/s40273-021-01019-4. Epub 2021 May 5.
8
The Increasing Economic Burden with Additional Steps of Pharmacotherapy in Major Depressive Disorder.在重度抑郁症中增加药物治疗步骤带来的经济负担增加。
Pharmacoeconomics. 2021 Jun;39(6):691-706. doi: 10.1007/s40273-021-01021-w. Epub 2021 Apr 28.
9
Economic Burden of Treatment-Resistant Depression among Adults with Chronic Non-Cancer Pain Conditions and Major Depressive Disorder in the US.美国慢性非癌症疼痛疾病患者和重度抑郁症成年患者中治疗抵抗性抑郁症的经济负担。
Pharmacoeconomics. 2021 Jun;39(6):639-651. doi: 10.1007/s40273-021-01029-2. Epub 2021 Apr 27.
10
Clinical characteristics of treatment-resistant depression in adults in Hungary: Real-world evidence from a 7-year-long retrospective data analysis.匈牙利成年治疗抵抗性抑郁症的临床特征：7 年回顾性数据分析的真实世界证据。
PLoS One. 2021 Jan 20;16(1):e0245510. doi: 10.1371/journal.pone.0245510. eCollection 2021.
Zotero 插件